Join
Live feed
·
PRReleasevia Quantisnow
Opus Genetics Inc. logo

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

ByQuantisnow·Wall Street's wire, on your screen.
IRD· Opus Genetics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IRD (Opus Genetics Inc.) and more on Quantisnow.